Tumor-derived OBP2A promotes prostate cancer castration resistance

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer (PCa); although most patients initially respond to ADT, almost all cancers eventually develop castration-resistant PCa (CRPC). Currently, most research focuses on castration-resistant tumors, and the role of tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Ji-Hak, Zhong, Shangwei, Li, Fuzhuo, Huang, Changhao, Chen, Xueyan, Liu, Qingqing, Peng, Shoujiao, Park, HaJeung, Lee, You Mie, Dhillon, Jasreman, Luo, Jun-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789742/
https://www.ncbi.nlm.nih.gov/pubmed/36547668
http://dx.doi.org/10.1084/jem.20211546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789742/
https://www.ncbi.nlm.nih.gov/pubmed/36547668
http://dx.doi.org/10.1084/jem.20211546

Ejemplares similares